A placebo-controlled, double-blind, randomized study to evaluate the efficacy and safety of TAK-475 [lapaquistat] 50 mg and 100 mg versus placebo, when co-administered with simvastatin 20 mg or 40 mg in subjects with primary dyslipidemia.

Trial Profile

A placebo-controlled, double-blind, randomized study to evaluate the efficacy and safety of TAK-475 [lapaquistat] 50 mg and 100 mg versus placebo, when co-administered with simvastatin 20 mg or 40 mg in subjects with primary dyslipidemia.

Completed
Phase of Trial: Phase III

Latest Information Update: 09 Jun 2013

At a glance

  • Drugs Lapaquistat (Primary) ; Simvastatin
  • Indications Hyperlipidaemia
  • Focus Registrational; Therapeutic Use
  • Sponsors Takeda
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 19 Jan 2009 Status changed from discontinued to completed.
    • 28 Mar 2008 Status changed from in progress to discontinued. According to a Takeda media release, development of lapaquistat is being discontinued.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top